Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacteria is a genus of probiotic bacteria that has been studied for its potential benefits in various gastrointestinal disorders, including colitis. Scientific evidence suggests that supplementation with Bifidobacteria may have a positive impact on colitis, particularly ulcerative colitis and, to a lesser extent, Crohn’s disease. Several randomized controlled trials and meta-analyses have investigated the use of Bifidobacteria, either alone or in combination with other probiotics, for the management of inflammatory bowel disease (IBD).

Proposed mechanisms for Bifidobacteria’s benefits include enhancement of the intestinal barrier, modulation of local and systemic immune responses, and suppression of pathogenic bacteria. Some studies have found that certain strains, such as Bifidobacterium longum and Bifidobacterium breve, can reduce disease activity and improve clinical symptoms in patients with mild to moderate ulcerative colitis. A few clinical trials have demonstrated that multi-strain probiotic formulations containing Bifidobacteria (such as VSL#3) can help maintain remission in ulcerative colitis and reduce inflammation, as measured by endoscopic and histological scores.

However, results are variable and not all studies show significant benefits. The quality of evidence is moderate, with limitations including small sample sizes, heterogeneity in probiotic strains and dosages, and short study durations. There is currently insufficient evidence to recommend Bifidobacteria as a primary therapy, but it may be considered as an adjunct to standard treatments for some patients.

More about Bifidobacteria
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Bifidobacteria

Products containing Bifidobacteria